toxic T lymphocyte immune response. However, in view of a potential clinic application of this finding, our exosome-based immunization strategy was faced with possible technical difficulties including industrial manufacturing, cost of production, and storage. To overcome these hurdles, we designed an as yet unproven exosome-based immunization strategy relying on delivery by intramuscular inoculation of a DNA vector expressing Nef mut fused with HPV E7. In this way, we predicted that the expression of the Nef mut /E7 vector in muscle cells would result in a continuous source of endogenous (ie, produced by the inoculated host) engineered exosomes able to induce an E7-specific immune response. To assess this hypothesis, we first demonstrated that the injection of a Nef mut /green fluorescent protein-expressing vector led to the release of fluorescent exosomes, as detected in plasma of inoculated mice. Then, we observed that mice inoculated intramuscularly with a vector expressing Nef mut /E7 developed a CD8 + T-cell immune response against both Nef and E7. Conversely, no CD8 + T-cell responses were detected upon injection of vectors expressing either the wild-type Nef isoform of E7 alone, most likely a consequence of their inefficient exosome incorporation. The production of immunogenic exosomes in the DNA-injected mice was formally demonstrated by the E7-specific CD8 + T-cell immune response we detected in mice inoculated with exosomes isolated from plasma of mice inoculated with the Nef mut /E7 vector. Finally, we provide evidence that the injection of Nef
Introduction
Exosomes are vesicles ranging 50-150 nm and are released constitutively by all cell types. 1 They are generated by inward invagination of endosome membranes. These intraluminal vesicles form the multivesicular bodies (MVBs) which can traffic to the plasma membrane to which they fuse, thereby releasing their vesicular contents in the extracellular milieu. Exosomes are part of the intercellular communication network. They incorporate messenger RNAs, microRNAs, DNA, and proteins which can be functional in target cells. Nanovesicles showing both physical and biochemical features resembling exosomes, but those generated through direct extrusion of plasma membrane have also been described in muscle cells.
The exosome immunogenicity basically relies on the amounts and quality of antigens they incorporate. Exosomes were tested as antitumor immunostimulatory agents, and clinical trials demonstrated that they are well tolerated as cell-free vaccines. 5, 6 However, their therapeutic efficacy appeared quite limited, posing the need of new methods to increase their immunogenicity. This issue has been addressed through in vitro methods devoted to engineer foreign antigens to increase their display on the exosome membrane. 7, 8 Exosome biogenesis and HIV budding share the functions of a number of cell proteins including Alix, Tsg101, and several components of the endosomal sorting complex required for transport. 9 The convergence of exosome and HIV biogenesis implies the possibility that viral products incorporate in exosomes. Such is the case for HIV-1 Nef, which associates with exosomes through anchoring its N-terminal myristoylation to lipid raft microdomains at the endosome membranes. 10 Nef is a 27 kilodalton (kDa) protein lacking enzymatic activities. However, it can act as a scaffold/adaptor element to trigger activation of signal transducing molecules. 11 We previously identified a 
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G Nef mutant incorporating in exosomes at quite high levels. 12 This Nef mutant (referred to as Nef mut ) is defective for basically all Nef functions. Its efficiency of incorporation in nanovesicles does not change significantly when fused at its C-terminus with foreign proteins. Manipulating Nef mut allows the incorporation of high amounts of antigens of choice into exosomes, which thus remain protected from external neutralization/degradation factors. We recently reported that the inoculation in mice of exosomes carrying HPV E7 fused with Nef mut induces an effective E7-specific CD8 + T cytotoxic lymphocyte (CTL) response. 13 This result demonstrates that, through the Nef mut -based engineering strategy, the already proven poor CTL immunogenicity of exosomes can be overcome. However, this strategy would face possible difficulties in view of potential clinical applications, including in areas of standardization of industrial manufacturing, high cost-effectiveness, and storage of the immunogen. For these reasons, we conceived a still unproven, exosomebased vaccine strategy relying on delivery of DNA vectors expressing Nef mut -based fusion proteins into host animal by intramuscular (IM) inoculation. This strategy relies on the very recent observation that muscle cells also, both proliferating and differentiated, constitutively release exosome-like vesicles. Considering that Nef mut and derivatives thereof associate with exosomes with high efficiency, we predicted that the expression of Nef mut -based vectors in muscle cells would be sufficient to create a continuous source of engineered, immunogenic exosomes.
Here, we demonstrate that IM inoculation of mice with a DNA vector expressing Nef mut /E7 elicits a potent CTL immune response, thereby blocking the growth of already implanted tumor cells. We provide evidence that the production of endogenously engineered exosomes was the basis of the observed antitumor effect. 
Materials and methods

Molecular constructs and cell cultures
Exosome isolation, detection, and characterization
Exosomes were isolated from cell supernatants through differential centrifugations as previously described. 18 The recovery of exosomes from the plasma of inoculated mice was carried out in a similar way except that samples were fivefold diluted before starting centrifugations. The amounts of recovered exosomes were evaluated by measuring the activity of acetylcholinesterase (AchE), ie, a classical exosome marker, 19 through the use of the Amplex Red kit (Molecular Probes, Thermo Fisher) following the manufacturer's recommendations. The AchE activity was measured in mU/mL, where 1 mU is defined as the amount of enzyme which hydrolyzes 1 pmole of acetylcholine to choline and acetate per minute at pH 8.0 at 37°C.
Fluorescent exosomes from transfected cell cultures were either directly detected by fluorescence-activated cell sorting (FACS, Gallios, Beckman Coulter, Brea, CA, USA), or, in the case of exosomes isolated from plasma, analyzed upon 
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Endogenously engineered exosomes as anti-HPV vaccine binding with aldehyde/sulfate latex beads (Molecular Probes, Thermo Fisher). To this end, samples were incubated with 5 µL of beads overnight at room temperature on a rotating plate, washed, and incubated for 1 hour at 4°C with either anti-CD63 mAb MX-49.129.5 from Abcam (Cambridge, UK) or a control isotype. The incubation was then repeated using secondary PE-conjugated Abs. Finally, beads were resuspended in 1× PBS-2% v/v formaldehyde and analyzed with FACS.
Western blot analyses of both cell lysates and exosomes were carried out as described previously. 12 Filters were revealed using 1:1,000 diluted sheep anti-Nef antiserum ARP 444 (a generous gift of M Harris, University of Leeds, Leeds, UK), 1:250 diluted anti-β actin AC-74 mAb from Sigma (Milan, Italy), and 1:100 diluted anti-Alix H-270 polyclonal Abs from Santa Cruz (Heidelberg, Germany).
Mice immunization and detection of IFN-γ-producing CD8 + T lymphocytes All studies with animals described here have been approved by the Ethical Committee of the Istituto Superiore di Sanità, Rome, Italy (protocol number 555/SA/2012) according to Legislative Decree 116/92, which has implemented in Italy the European Directive 86/609/EEC on laboratory animal protection. Animals used in our research have been housed and treated according to the guidelines mentioned in the Legislative Decree. C57 Bl/6 mice were purchased from Charles River Laboratories Italia (Calco, Italy) and inoculated IM two times at 10 day intervals with 50 µg in each quadriceps with plasmid DNA purified with endotoxin-free Qiagen kit (Hilden, Germany). Mice were also inoculated subcutaneously (SC) three times at ten day intervals with exosomes (6 mU AchE equivalents) purified from plasma of DNA injected mice, and sacrificed 10 days after the last immunization. To detect both E7-and Nef-specific CD8 + T-cell immune responses, splenocytes were put in IFN-γ Elispot microwells (Millipore, Billerica, MA) in the presence of 5 µg/mL of either HPV E7 or HIV-1 Nef 8-or 9-mer peptides binding the H-2 K b complex of C57 Bl/6 mice, ie, DLYCYEQL (aa 21-28) and RAHYNIVTF (aa 49-57) for E7, 20 and TAATNADCA (aa 48-56) for Nef.
21
H-2 K b binding HPV E6-specific KLPQLCTEL (aa 18-26) and YDFAFRDL (aa 50-57) peptides 20 were used as unrelated peptides. After overnight incubation, IFN-γ Elispot plates were developed (Mabtech AB, Nacka Strand, Sweden) and spot-forming units were counted using an Elispot reader (A.EL.VIS. Elispot reader and Analysis software GmbH, Turin, Italy).
Fluorescence microscope analysis
Slices (7 µm) from quadriceps of inoculated mice were prepared using a cryostat (Leika CM 3050, Wetzlar, Germany) and placed to slides. The slices were then incubated with 4′,6′-diamidino-2-phenylindole (DAPI; Vector Laboratories, Peterborough, UK) together with an antifade mounting medium. Finally, coverslips were mounted on the slides, which were then observed with a Zeiss Axioskop 2 Plus (Oberkochen, Germany) fluorescence microscope.
CTL assay
CD8
+ T-cells were isolated from splenocytes by positive immunomagnetic selection (Miltenyi Biotec Gmbh, Teterow, Germany). They were put in coculture for 6 hours in RPMI 10% FCS with EL-4 cells previously labeled with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, Thermo Fisher), following the manufacturer's recommendation, and treated overnight with either E7 or unrelated peptides. The cocultures were run at different cell ratios (ie, 20:1, 10:1, and 5:1 effector/target cells) in 200 µL of RPMI 20% in U-bottom 96 well plates. Afterward, EL-4 cell mortality was scored by FACS analysis soon after addition of 7-AAD at final concentration of 1 µg/mL.
Detection of anti-E7 and anti-Nef antibodies in plasma
Plasma from inoculated mice were pooled, and twofold serial dilutions starting from 1:10 were assayed for the presence of both E7-and Nef-specific Abs as previously described. 22 The end-point dilution corresponded to a ,0.1 OD absorbance at 450 nm. Each plasma sample was assayed in triplicate, and the mean of the absorbance values was taken as final readout.
antitumor effects of Nef mut /E7-expressing vector
The antitumor activity was evaluated in mice previously challenged with 2×10 5 TC-1 cells. DNA inoculations were performed 4 and 11 days after tumor cell challenge following the above reported protocol, and only in mice that developed palpable tumors. Tumor growth was monitored by visual inspection, palpation, and measurement of tumor nodule diameter calculated as (length × width 2 )/2. At the end of the observation time, tumors were explanted and weighted.
Statistical analysis
When appropriate, data are presented as mean + standard deviation. In some instances, the paired Student's t-test was 
Results
Detection of engineered exosomes released by DNA-transfected murine muscle cells
We preliminarily investigated whether, as already assessed in different human cell types, the expression of a Nef mutexpressing DNA vector in murine muscle cells was sufficient to generate engineered exosomes. For the sake of clarity, exosome-like nanovesicles released by murine muscle cells are here defined as exosomes, although their biogenesis somehow differs from that of MVB-generated exosomes. 2 Murine muscle C 2 C 12 and, as control, human 293T cells were transfected with vector expressing GFP fused at the C-terminus of either Nef mut or a Nef isotype inefficiently associating with exosomes (ie, Nef G2A ). 23 Transfected cells were monitored for the respective efficiency of transfection ( Figure 1A) , which in muscle cells appeared to be over 50%. The supernatants were collected, and exosomes isolated through differential centrifugation. Exosome preparations were then titrated in terms of AchE activity. The two cell types produced apparently similar levels of AchE-positive 
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Endogenously engineered exosomes as anti-HPV vaccine nanovesicles whatever the transfection conditions ( Figure 1B) . The western blot analysis of 100 µU equivalent of exosomes showed the presence of Nef-derived molecules in exosomes from both 293T and C 2 C 12 cells transfected with Nef mut / GFP but not Nef G2A /GFP vectors ( Figure 1C ). The FACS analysis confirmed the association of fluorescence with the nanovesicles we recovered from C 2 C 12 cells transfected with Nef mut /GFP ( Figure 1D ). In sum, we have proven that exosome-like nanovesicles released by murine muscle cells can be engineered by Nef mut -derivatives as previously proven in epithelial-like, human 293T cells.
Nef mut -derived products can be detected in exosomes from plasma of DNAinoculated mice
To assess whether engineered exosomes can be generated in vivo, 50 µg of either Nef mut /GFP, Nef G2A /GFP, or empty vector were inoculated in each quadriceps of C57 Bl/6 mice. To assess the expression of injected vectors, 3 days later, slices of muscle tissues obtained from the zones of inoculation were analyzed for the expression of GFP-related products. Consistently with what was already described for wt Nef, 24 Nef mut accumulated at the plasma membrane as well as in an intracellular punctate pattern. Differently, the Nef G2A mutant localized preferentially in the cytoplasm, as a consequence of the lack of N-terminal myristoylation (Figure 2A ). Three and nine days after inoculation, plasma from the inoculated mice was recovered and exosomes were isolated by differential centrifugations. Exosome preparations were titrated in terms of AchE activity, equivalent amounts of them were bound to white aldehyde/sulfate latex beads, and finally labeled for the CD63 exosome marker. By FACS analysis of the exosomebead complexes, we detected fluorescent exosomes among those isolated only from the plasma of mice injected with Nef mut /GFP vector ( Figure 2B ). were inoculated IM in each quadriceps with 50 µg of vectors expressing either Nef mut /E7 or E7 alone or empty vector. Since we previously noticed that E7 associates with exosomes at undetectable levels (not shown), the inclusion of a vector expressing E7 alone was instrumental to evaluate the benefit of the Nef mut fusion in terms of CD8 + T-cell immunogenicity. The inoculations were repeated 10 days later, and after additional 10 days mice were sacrificed. Then, the splenocytes were isolated and cultured overnight in IFN-γ Elispot 
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Endogenously engineered exosomes as anti-HPV vaccine microwells in the presence of either unrelated, Nef-, or E7-specific nonamers. The CD8 + T-cell activation observed in cultures with unrelated peptides remained at background levels as in the case of splenocytes cultured in the absence of peptides (not shown). On the other hand, peptide-specific cell activation was clearly detectable in splenocytes from mice inoculated with Nef mut /E7-expressing vector ( Figure 3A) . Conversely, no CD8 + T-cell response was observed in cultures of splenocytes from mice receiving either E7-expressing or empty vector, whatever the peptide used. Notably, anti-E7 antibodies were detected only in plasma from mice inoculated with the vector expressing E7 alone ( Figure 3B ).
To evaluate whether the CD8 + T-cell response coupled with an E7-specific CTL activity, CD8
+ T-cells were isolated from pools of splenocytes and then put in coculture for 6 hours at different cell ratios with CFSE-labeled EL-4 cells pretreated overnight with either unrelated or E7 nonamers. Afterward, the cocultures were labeled with 7-AAD and percentages of dead target cells were scored by FACS analysis. The results reported in Figure 3C show a clear increase of target cell mortality in both 20:1 and 10:1 cocultures comprising CD8 + T lymphocytes from mice inoculated with the Nef mut /E7-expressing vector and EL-4 pretreated with E7-specific nonamers. This result demonstrates the presence of E7-specific CTLs among the CD8 + T lymphocytes isolated from mice inoculated with the Nef mut / E7-expressing vector.
Taken together, these data indicated that IM inoculation of a vector expressing a heterologous antigen fused with Nef mut leads to the induction of a strong antigen-specific CTL response in the absence of antibody production.
Lack of immunogenicity of a DNA vector expressing the wt Nef isoform
To support the idea that high levels of Nef mut incorporation in exosomes were mandatory to elicit the antigen-specific CD8 + T-cell response, we reproduced the immunogenicity experiments by inoculating mice with vectors expressing the wt isoform of Nef, which is known to incorporate in exosomes at much lower extents compared to Nef mut . 12 To this end, C57 Bl/6 mice (four per group) were injected IM in each quadriceps with 50 µg of a vector expressing either wt Nef or Nef mut or with the empty vector. The inoculations were repeated 10 days later, and after an additional 10 days the mice were sacrificed. Splenocytes were then isolated and cultured overnight in IFN-γ Elispot microwells in the presence of either unrelated or Nef nonamers. As shown in Figure 4 , mice inoculated with the vector expressing wt Nef, differently to those receiving the Nef mut vector, failed to develop a detectable Nef-specific CD8 + T cell response. This result indicates that the levels of antigen incorporation into exosomes are critical for the immune response, meanwhile suggesting that the functions of wt Nef were not per se involved in the antigen-specific CD8 + T-cell activation.
Immunogenicity of exosomes isolated from plasma of mice immunized with Nef mut /E7 DNA To enforce the hypothesis that the CD8 + T-cell immune response we detected upon inoculation of Nef mut -expressing vectors relied on production of engineered exosomes, we next tested whether exosomes purified from plasma of DNAinoculated mice were immunogenic in recipient-naïve mice. For this, eight mice were inoculated with vectors expressing E7, Nef mut /E7, or empty vector following the schedule mentioned earlier. Eight days after the last immunization, peripheral blood mononuclear cells were recovered through retro-orbital bleeding and checked for the E7-specific CD8 + T-cell response. As already observed, the injection of the Nef mut /E7-expressing vector, but not that expressing E7 alone, gave rise to a well detectable E7-specific CD8 + T-cell response ( Figure 5A) . Plasma from the different mouse groups were pooled and exosomes were isolated by differential centrifugation. Afterward, exosomes were titrated in terms of AchE activity, and 6 mU AchE equivalents were injected SC in syngeneic mice three times at 10 day intervals. Finally, mice were sacrificed, and splenocytes tested for the E7-specific CD8 + T-cell responses, which were noticed only in splenocyte cultures from mice inoculated with exosomes purified from mice injected with the Nef mut /E7 DNA vector ( Figure 5B) .
These results indicate that the IM injection of DNA expressing Nef mut /E7 leads to the production of immunogenic exosomes, hence further supporting the idea that the production of endogenously engineered exosomes was on the basis of the strong E7-specific CD8 + T-cell immune response observed in the DNA-injected mice.
antitumor therapeutic effect of IM inoculation of Nef mut /E7-expressing DNA vector 
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Endogenously engineered exosomes as anti-HPV vaccine immunization assays on C57 Bl/6 mice inoculated SC with 2×10 5 TC-1 cells. Mice developing a tumor mass detectable by palpation, ie, of about 2 mm diameter, were then inoculated with 50 µg/quadriceps of vectors expressing either empty vector, Nef mut (four mice per each group) or Nef mut /E7 (six mice) at days 4 and 11 after cell implantation. As control, 4 tumor-implanted mice were injected with the vehicle alone. At day 21, retro-orbital bleeding was carried out on mice injected with Nef mut -or Nef mut /E7-expressing vectors to assess the induction of E7-specific CD8 + T-cell immune response ( Figure 6A ). The growth of tumors was monitored over 30 days, and thereafter mice were sacrificed, tumors explanted, and weighted. Figure 6B shows that, whereas the injection of control DNA vectors did not influence the growth of implanted tumor cells, their expansion was severely impaired in mice inoculated with Nef mut /E7 vector, with tumor cells apparently being cleared in three mice, as confirmed by tumor weights ( Figure 6C) .
Hence, the inoculation of Nef mut /E7-expressing DNA vector elicited a CD8 + T-cell immune response also in the presence of tumor cells. Most importantly, this immune response was both strong and rapid enough to inhibit the tumor growth and, in some instances, clear the implanted tumor cells.
Taken together, these results represent a relevant milestone toward possible therapeutic applications of immunization strategies based on Nef mut -based endogenously engineered exosomes.
Discussion
We here describe a simple exosome-mediated strategy to induce unrestricted CTL immunity through IM DNA inoculation. Muscle cells constitutively release exosome-like nanovesicles through extrusion of plasma membrane with a biogenesis at least in part different from that of MVB-generated exosomes. Thus, considering that Nef mutbased in vitro engineered exosomes we previously described were generated in epithelial-like human cells, investigating whether and how efficiently the ectopic expression of Nef mut leads to the release of engineered exosomes in murine cells was mandatory. Data we obtained with C 2 C 12 cells supported the idea that Nef mut accumulates into exosome-like nanovesicles released by murine muscle cells at levels similar to those observed in human cells. Our investigations did not include terminally differentiated muscle cells, ie, the cell type most likely targeted by IM inoculation in mice, since we assumed that the cell differentiation does not significantly impact the mechanisms underlying intracellular vesicle trafficking. Since we expected that the majority of muscle cells targeted by IM DNA inoculation was differentiated, the detection of engineered exosomes in plasma from inoculated mice supported the idea that terminally differentiated muscle cells indeed release engineered exosomes in vivo. We cannot exclude that at least part of injected DNA could target other cell types by means, for instance, of the diffusion of DNA in draining lymph nodes, where it can be captured and internalized by dendritic cells (DCs). However, we believe that DCs contribute limitedly to the overall production of engineered exosomes since SC inoculation of Nef mut /E7-expressing DNA, which is expected to preferentially target DCs, gave rise to a quite weak E7-specific CD8 + T-cell activation (not shown).
The immune response detected in DNA-inoculated mice appeared much stronger than what we previously observed in mice injected with in vitro produced engineered exosomes. 13 A direct comparative experiments cannot be run in view of the different nature of the two immunogens. However, we noticed that the DNA inoculation elicited an E7-specific CD8 + T-cell activation strong enough to be clearly detected without the in vitro, peptide-directed stimulation/expansion of specific CD8 + T lymphocytes which, on the contrary, was required to detect the immune response in mice inoculated with in vitro produced exosomes. 13 This apparently stronger immunogenicity was likely a consequence of the continuous release from DNA-recipient muscle cells of immunogenic exosomes ready to be internalized by both local and distal antigen-presenting cells. Differently, it is known that both in vitro and ex vivo produced exosomes have a quite short half-life upon injection, ie, about 2 minutes, with a prompt accumulation in liver and spleen, and only residual amounts detectable after 4 hours. [25] [26] [27] [28] The detection of fluorescent exosomes in plasma of mice inoculated with Nef mut /GFPexpressing vector represented a key finding supporting the idea that engineered exosomes can indeed be produced upon DNA injection. The lack of Nef-specific CD8 + T-immune response in mice injected with wt Nef highlighted the importance for the immune response of the efficient association with exosomes, meanwhile excluding the involvement of other Nef functions. Similarly, no E7-specific CD8 
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Endogenously engineered exosomes as anti-HPV vaccine with exosomes poorly, in the presence, however, of a well detectable anti-E7 antibody production. This result further supports the idea that high levels of antigen incorporation into exosomes are mandatory to elicit a strong antigen-specific CTL activity. 
Conclusion
The data reported here allow us to propose a novel strategy to induce CTL immunity based on endogenously engineered exosomes. The major advantages of our vaccine platform are the cost-effectiveness of immunogens, ease of storage, potent immunogenicity, and significant intrinsic flexibility in terms of choice of the immunogen.
